At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Progenics Pharmaceuticals
- Class Small molecules; Vitamins
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued CNS disorders; Stomatitis; Stroke
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 26 Aug 2005 No development reported - Preclinical for CNS disorders in USA (unspecified route)
- 26 Aug 2005 No development reported - Preclinical for Stomatitis in USA (Topical)